[18F]ZCDD083: a PFKFB3-targeted PET tracer for atherosclerotic plaque imaging by De Dominicis, Carlo et al.
Subscriber access provided by Library, Special Collections and Museums, University of Aberdeen
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Letter
[18F]ZCDD083: a PFKFB3-targeted PET
tracer for atherosclerotic plaque imaging
Carlo De Dominicis, Paola Perrotta, Sergio Dall'Angelo, Leonie
Wyffels, Steven Staelens, G. R. Y. de Meyer, and Matteo Zanda
ACS Med. Chem. Lett., Just Accepted Manuscript • DOI: 10.1021/acsmedchemlett.9b00677 • Publication Date (Web): 19 Feb 2020
Downloaded from pubs.acs.org on February 21, 2020
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
TOC Graphic
Page 1 of 21
ACS Paragon Plus Environment
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ABSTRACT: PFKFB3, a glycolysis-related enzyme upregulated in inflammatory conditions and angiogenesis, is an emerging 
target for diagnosis and therapy of atherosclerosis. The fluorinated phenoxindazole [18F]ZCDD083 was synthesised, 
radiolabelled in 17 ±5% radiochemical yield and >99% radiochemical purity, and formulated for pre-clinical PET/CT imaging 
in mice. In vivo stability analysis showed no significant metabolite formation. Biodistribution studies showed high blood pool 
activity and slow hepatobiliary clearance. Significant activity was detected in the lung 2 h post-injection (pi) (11.0 ±1.5 
%ID/g), while at 6 h pi no pulmonary background was observed. Ex vivo autoradiography at 6 h pi showed significant high 
uptake of [18F]ZCDD083 in the arch region and brachiocephalic artery of atherosclerotic mice, and no uptake in control mice, 
matching plaques distribution seen by lipid staining along with PFKFB3 expression seen by immunofluorescent staining. In 
vivo PET scans showed higher aortic region uptake of [18F]ZCDD083 in atherosclerotic ApoE-/-Fbn1C1039G+/- than in control 
mice (0.78 ± 0.05 vs 0.44 ± 0.09 %ID/g). [18F]ZCDD083 was detected in aortic arch and brachiocephalic artery of ApoE-/- 
(with moderate atherosclerosis) and ApoE-/-Fbn1C1039G+/- (with severe, advanced atherosclerosis) mice, suggesting this tracer 
may be useful for the non-invasive detection of atherosclerotic plaques in vivo.
KEYWORDS: Atherosclerosis, Plaque, Fluorine, PET 
imaging, glycolysis, preclinical.
INTRODUCTION
Atherosclerosis is a pathological process characterised by 
progressive accumulation of lipids, inflammatory cells and 
connective tissue in the arterial wall.1 This process, leading 
to the formation of the so-called “atherosclerotic plaques”, 
is predominantly asymptomatic. However, the progression 
of the disease can cause progressive stenosis of arterial 
lumen, which can eventually result in ischaemic heart pain. 
Acute clinical events, such as myocardial infarction, stroke 
and unstable angina, are mainly associated with instability 
of plaques and formation of occlusive thrombi.2 
The progression of atherosclerotic plaques is initially 
asymptomatic, characterised by the slow growth of “silent” 
stable plaques. However, plaque rupture is associated with 
unstable angina, acute myocardial infarction, and sudden 
cardiac death. Similarly, rupture of carotid artery plaque is 
associated with cerebral ischemic events.3 The risk of 
thrombotic complications of atherosclerosis is mostly 
related to the instability of an atheroma rather than the size 
of the plaque. 
Currently, cardiovascular medicine aims principally to 
identify atherosclerotic plaques prone to rupture, improve 
the risk stratification, monitor the disease progression, 
assess new anti-atherosclerotic therapies and promptly 
evaluate the efficacy of therapeutic treatment. PET imaging 
is non-invasive and has a great potential in this context, but 
there is a clear need for new targets and radiotracers for 
imaging unstable atherosclerotic plaque.4,5 
The PFKFB3 enzyme is emerging as a new target for the 
in vivo assessment of atherosclerotic plaques.6,7 PFKFB3 is a 
glycolysis-related enzyme upregulated in inflammatory and 
hypoxic conditions.8,9 Several studies have shown a 
correlation between PFKFB3 and angiogenesis, which is a 
feature of vulnerable atherosclerotic plaques.10,11,12,13 Here 
we describe the development of the 18F-radiolabelled 
phenoxindazole compound ZCDD083 as a PFKFB3-
targeted PET radiotracer for imaging the atherosclerotic 
plaque in vivo.14 ZCDD083 is a close structural mimic of the 
potent inhibitor AZ68 (IC50= 4nM), whose radiofluorination 
was deemed to be chemically viable and unlikely to affect 
the binding to PFKFB3.
RESULTS
Phenol intermediate 2 (Scheme 1) was synthesised from 
N-Boc-proline and O-Bn-4-aminophenol, which were 


























Scheme 1. Synthesis of phenol intermediate 2.
Indazole 4 (Scheme 2) was synthesised by NIS-promoted 
iodination of (2-amino)phenyl-acetonitrile, followed by 
indazole ring formation via Sandmeyer reaction and 
intramolecular ring closure of the diazonium salt formed 
from 3.
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Scheme 2. Synthesis of indazole 4.
The radiofluorination precursor 7 (Scheme 3) was 
synthesized next. Commercial 2-methyl-1,3-propanediol 
was treated with tosyl chloride to give the mono tosylated 
derivative 5, which was reacted with the indazole 4 via 
Mitsunobu reaction to give compound 6. Ullmann-type 
coupling with phenol 2 afforded the target tosylated 
precursor 7.




























Scheme 3. Synthesis of radiofluorination precursor 7.
The ‘cold’ (e.g. non-radioactive) tracer ZCDD083 
(Scheme 4) was prepared from the indazole tosylate 6, 
which was treated with TBAF to give the fluorinated 
compound 8. The latter was subjected to the Ullmann 
coupling with 2 affording 9, which was N-Boc-deprotected 









































Scheme 4. Synthesis of ‘cold’ ZCDD083.
Starting from the tosylated precursor 7, [18F]ZCDD083 
was radiosynthesised in a two-step synthesis (Scheme 5) 
using standard 18F-fluoride chemistry, producing first the 
protected tracer 10 which was then treated with HCl in 





































Scheme 5. Radiosynthesis of [18F]ZCDD083.
[18F]ZCDD083 was obtained with a 17 ±5% 
radiochemical yield (decay-corrected to EOB) and the 
activity was in the range of 4.7-7.2 GBq (n = 7). The average 
time taken for synthesis, purification and formulation was 
65 minutes. [18F]ZCDD083 was obtained with 
radiochemical purity >99%, specific activity >130 
GBq/μmol, no impurities were detected in the UV 
chromatogram (Fig. 1) and no residual solvents other than 
ethanol (<10%) were detected (see Fig. S4, Supporting 
Information).
Figure 1. Chemical and radiochemical purity of 
[18F]ZCDD083 assessed by analytical RP-HPLC. No impurities 
were detected in the UV (top) and radioactive (bottom) 
chromatograms. Column: Phenomenex Luna C18 column (5 
µm, 100 Å, 250 × 4.6 mm). Mobile phase: solvent A = H2O + 
0.1% TFA, solvent B = CH3CN + 0.1% TFA; Isocratic method 
40% B.
A preliminary metabolite study was performed in healthy 
C57BL/6J mice (6 weeks old, female) to evaluate the in vivo 
plasma stability of [18F]ZCDD083. The radio-HPLC analysis 
showed no significant metabolite formation within 6 h. The 
eluate from HPLC was collected in fractions and the 
radioactivity in each fraction was measured in a γ-counter. 
At 6 h pi, 78.9% ±1.2 of [18F]ZCDD083 was intact (see Table 
S1 and Fig. S5, Supporting Information).
Ex vivo biodistribution of [18F]ZCDD083 was initially 
studied in healthy female C57BL/6J mice (Table S2, Supp 
Information). Measurement of radioactivity by γ-counter 
showed a high overall accumulation of [18F]ZCDD083 in 
tissues and organs within 2 h pi, as shown in Fig. 2. More 
specifically, high blood radioactivity was observed (7.2 ±2.2 
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%ID/g at 15 min pi, 5.5±1.6 %ID/g at 1 h pi, and 2.1±0.4 
%ID/g at 2 h pi), revealing a slow clearance of 
[18F]ZCDD083 from blood pool. Also, high pulmonary 
uptake was found (34.7 ± 6.0 %ID/g at 15 min) with a slow 
washout from lungs (11.0 ± 1.5 %ID/g at 2 h. On the 
contrary, at 6 h pi the radioactivity in lungs and blood was 
significantly lower (5.5±3.9 %ID/g and 1.5±1.1 %ID/g 
respectively). Instead, at the late time point [18F]ZCDD083 
had mostly accumulated in the excretory organs (i.e. 25.5 ± 
3.8 %ID/g in small intestine and 47.9 ± 6.4 %ID/g in large 
intestine). Level of uptake in the liver and the intestines 
were significantly higher compared to the kidneys. 
Therefore, it can be concluded that [18F]ZCDD083 is 
predominantly cleared via the hepatobiliary system into the 
intestines and that the renal clearance is less significant.
Ex vivo biodistribution evaluation at 6 h pi was carried out 
also in atherosclerotic ApoE-/- mice (Table S3, Supp 
Information). A similar [18F]ZCDD083 biodistribution 
profile was observed in atherosclerotic ApoE-/- and control 
C57BL/6J mice. Pharmacokinetic studies in ApoE-/- 
atherosclerotic mice confirmed the plasma half-life of 
[18F]ZCDD083 (1.4 ±0.2 %ID/g in blood). Residual high 
radioactivity accumulation was observed in lungs (8.6 ± 1.9 
%ID/g), whereas the maximal uptake was found in small 


































































Figure 2. Ex vivo biodistribution of [18F]ZCDD083. Slow blood clearance and high tracer uptake in the lungs were observed at 
earlier time points within 2 h pi. At 6 h pi [18F]ZCDD083 was mostly accumulated in the intestines.
[18F]ZCDD083 PET imaging scans were performed using 
two different disease models (ApoE-/-, with moderate 
atherosclerosis, and ApoE−/−Fbn1C1039G+/−, with severe 
advanced atherosclerosis, both female) and aged-matched 
wild type C57BL/6J female mice as controls. Representative 
PET/CT scans of ApoE-/-Fbn1C1039G+/- mice are shown in 
Fig. 3. Spherical ROIs were drawn manually over each aortic 
arch and ascending aorta using the axial view of CT images. 
The [18F]ZCDD083 signal was then quantified as SUVmean 
(mean Standardized Uptake Values). Tracer uptake was 
different in ApoE-/-Fbn1C1039G+/- (SUV 0.78 ± 0.05), ApoE-/- 
(SUV 0.55 ± 0.06) and C57BL/6J mice (SUV 0.44 ± 0.09), 
with significant difference between first and latter series, as 
shown in Fig.  4. Figure 3. Representative axial, sagittal and coronal views of 
PET/CT images of ApoE-/-Fbn1C1039G+/-acquired at 6 h 
after injection of [18F]ZCDD083. Radioactive signal in aorta 
(white arrows) was observed.
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Figure 4. Comparison of SUV measurements in C57BL/6J (n 
= 6), ApoE-/- (n = 6) and ApoE−/−Fbn1C1039G+/− mice (n = 
2). All values are given as mean ± SD. One-way ANOVA was 
performed to test for difference between groups. One 
ApoE−/−Fbn1C1039G+/− mouse was excluded from the 
analysis because of a PET image acquisition technicality. 
(***p = 0.0006, one-way ANOVA followed by Brown-Forsythe 
test).
Figure 5. [18F]ZCDD083 aortic uptake vs plaque distribution. Ex vivo autoradiography (left part of the insets) and fat staining 
using Oil-red O (right part of the insets) of longitudinally opened aortas at 6h post injection of [18F]ZCDD083 in C57BL/6J control 
mice (left) compared to atherosclerotic mice (ApoE-/- and ApoE-/-Fbn1C1039G+/-, centre and right respectively, as indicated by the 
white arrows. [18F]ZCDD083 uptake colocalises with atherosclerotic plaques. Scale bar = 1 cm.
At the end of the PET imaging scans, three mice of 
C57BL/6J, ApoE-/- and ApoE−/−Fbn1C1039G+/− were sacrificed 
and the aorta was harvested for Red Oil O staining and 
autoradiography (ARG). The ex vivo distribution of 
atherosclerotic plaques within the aorta was assessed by 
Red Oil O staining, whereas the accumulation of 
[18F]ZCDD083 was assessed by autoradiography of the in 
vivo injected [18F]ZCDD083. This aforementioned Red Oil O 
staining and ex vivo autoradiography were performed on 
the same aortic specimens in order to visually compare fat-
stained areas and tracer distribution within the aorta (Fig. 
5). 
Aortas from C57BL/6J control mice did not show focal 
lipid stained areas and radioactivity signal. Conversely, 
atherosclerotic plaques were found in ApoE-/- mice, 
especially in the aortic arch, proximal aorta and 
brachiocephalic aorta. The Oil Red O staining showed also a 
low plaque load in the thoracic descending aorta of the 
ApoE−/− strain. The ARG of the same specimen showed that 
the tracer accumulation within the aorta matched exactly 
with the distribution of atherosclerotic lesions. More 
specifically, the radioactivity was accumulated mostly in the 
aortic arch and in the branches. In these regions, 
[18F]ZCDD083 uptake was significantly higher in ApoE−/− 
(0.022 ± 0.004 %ID/µL) than control mice (0.011 ± 0.003 
%ID/µL) (p = 0.0378, unpaired t test). 
The correlation between plaques and tracer uptake was 
also consistent using ApoE−/−Fbn1C1039G+/− mice with higher 
plaque load than the ApoE−/− strain.27 The comparison of 
corresponding en face lipid staining and ARG signals 
demonstrated a high correlation of fat-stained areas and 
radioactivity distribution. ApoE−/−Fbn1C1039G+/− mice 
showed more extended atherosclerotic lesions in the arch 
region, brachiocephalic artery along with thoracic 
descending aorta. [18F]ZCDD083 was, indeed, detected in 
the same areas along the aorta. 
Aortic specimens of C57BL/6J and ApoE-/- (n = 3/ each 
group) were used for further histological analysis after PET 
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imaging scans. Longitudinal sections of aortic arch and right 
common carotid artery as well as cross sections of 
brachiocephalic aorta and proximal aorta were stained with 
haematoxylin and eosin (H&E) to visualise atherosclerotic 
plaques and lesion morphology. Aortas of healthy mice did 
not show atherosclerosis, whereas ApoE-/- mice showed 
fibrous/atheromatous plaques and some small 
calcifications. The H&E staining confirmed atherosclerotic 
disease especially in brachiocephalic artery, proximal aorta 
and aortic arch. The immunohistochemistry of ApoE-/- 
aortic arch sections, revealed that the enzyme target 
PFKFB3 is overexpressed inside atherosclerotic plaques 
(see Fig. S6, Supporting Information).
The comparison among brachiocephalic arteries of 
atherosclerotic and control mice showed that PFKFB3 was 
highly expressed within atherosclerotic plaques, whereas in 
normal vessels PFKFB3 is present just in a basal level along 
the arterial wall (Fig. 6). 
Figure 6. Immunohistochemistry of murine brachiocephalic 
arteries. Upper panels = immunofluorescent staining for von 
Willebrand factor to detect endothelial cells (green) and 
PFKFB3 (red). Counter-staining with DAPI to detect nuclei 
(blue). Lower panels = PFKFB3 staining (red). ApoE-/- mice 
exhibit high expression level of PFKFB3 enzyme in contrast to 
C57BL/6J controls. Scale bar = 50 µm.
DISCUSSION
Atherosclerosis is responsible for the majority of acute 
cardiovascular events. Specifically, rupture of 
atherosclerotic plaques and consequent thrombosis 
remains the largest underlying cause of cardio- and 
cerebrovascular death. Despite extraordinary advances in 
the understanding of the pathophysiology of 
atherosclerosis, both the diagnosis and treatment of the 
disease still present limitations. Currently, the main 
challenge in cardiovascular medicine is to identify patients 
who are at risk of coronary plaque rupture and subsequent 
heart attack or stroke originating from carotid plaque 
depositions.15 Among the cardiovascular imaging 
modalities used, coronary angiography has a wide clinical 
application but provides information only on vessel 
stenosis. Other imaging techniques, such as intravascular 
ultrasound (IVUS), optical coherence tomography (OCT) 
and near-infrared spectroscopy (NIRS), can provide only a 
limited plaque characterisation but, unfortunately, they are 
invasive and thus not useful for patient diagnosis and follow 
up.16,17,18 Therefore, new non-invasive approaches to detect 
potentially unstable plaque are urgently needed. 
In this context, PET imaging has great potential, since - 
compared to other molecular imaging modalities - it shows 
higher sensitivity allowing better visualisation of biological 
and biochemical processes involved in the development of 
atherosclerotic plaques.19 [18F]FDG (inflammation, 
approved for clinical use) and [18F]NaF (micro-calcification) 
have been investigated in a clinical setting for detection and 
characterisation of atherosclerotic plaques in the major 
coronary arteries.19,20 However, new targets and 
radiotracers are currently being investigated preclinically 
for imaging atherosclerotic plaque.21 Clinical studies 
showed that 18F-FDG is useful to assess carotid artery 
stenosis in asymptomatic patients.22,23 However, carotid 
artery imaging using 18F-FDG PET is challenging due to (1) 
the low spatial resolution of PET (≈ 3 mm in human PET and 
1.2 mm in rodent PET, using our setting), (2) cardiac motion 
and (3) myocardial spill over.24 To address the latter 
limitation, new imaging targets and radiotracers having 
lower unspecific myocardial uptake are currently under 
investigation.25 
The results above validate the PFKFB3 enzyme as an 
imaging target of atherosclerosis in two mouse models.26,27 
Firstly, we observed – via PET/ARG – an increased target 
engagement in cross sections of diseased aortas of 
atherosclerotic mice compared to those of healthy mice. 
Secondly, longitudinal sections of aortic arch specimens of 
ApoE-/- mice showed higher expression level of PFKFB3 
enzyme within atherosclerotic plaques compared to normal 
vessel wall. Hence, all these results demonstrated the 
appropriateness and the specificity of the PFKFB3 target for 
the detection of atherosclerotic plaques.
The new PFKFB3-targeted tracer, [18F]ZCDD083 could be 
obtained in high radiochemical yields, activity 
concentrations and quality parameters. [18F]ZCDD083 
demonstrated high in vivo metabolic stability and long 
circulation time in the blood. The slow clearance from the 
blood may be explained by the high hydrophobicity of 
[18F]ZCDD083. Indeed, a LogD7.4 of 3.6 was reported for the 
parent compound AZ68.14 The correlation of high 
hydrophobicity with high binding to plasma proteins and 
prolonged circulation time in the blood is well known.28 
High binding to plasma proteins is documented for the 
compound AZ2614 (chemically similar to AZ68) and might 
be valid also for our tracer [18F]ZCDD083. This may likely 
explain the slow tracer clearance. Also, the excretion route 
is usually related to lipophilicity, as lipophilic compounds 
are generally cleared via the hepatobiliary system. This is in 
accordance with our ex vivo biodistribution results which 
showed a predominant excretion from the liver to the 
intestines. We also noticed a high uptake in the lung. 
However, it is not clear whether this high uptake in the lung 
is due to nonspecific binding (due to the high [18F]ZCDD083 
lipophilicity) or somehow correlated with PFKFB3 tissue 
distribution. In 2003, Minchenko et al. studied the in vivo 
expression of the PFKFB enzyme family and its response to 
hypoxia, disclosing that lungs exhibit high basal level of 
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PFKFB3 mRNA.29 Furthermore, it was recently shown that 
lung endothelial cells express high levels of glucose 
metabolic enzymes, such as PFKFB3.30 Finally, the proteome 
analysis reported in the Human Protein Atlas shows that 
lung, stomach and placenta have the highest PFKFB3 
expression among all tissues considered.31 
Our PET imaging studies showed significantly increased 
signals in the aorta of ApoE-/- (+25%) and 
ApoE−/−Fbn1C1039G+/− (+79%) compared to C57BL/6J mice. 
This is in accordance with the higher plaque burden in 
ApoE−/−Fbn1C1039G+/− mice compared to ApoE-/- mice.27 
Moreover, these results were supported by aortic 
autoradiography which showed a 2-fold increased uptake in 
the aortic arch of ApoE-/- compared to WT mice. The 
autoradiographic signal in ApoE−/−Fbn1C1039G+/− was 
considerably higher too. The increment in uptake is clearly 
correlated with the increment in plaque load, as confirmed 
by histological evaluation. Indeed, the highest uptake was 
found in ApoE−/−Fbn1C1039G+/− at an advanced stage of the 
disease and high level of plaques in the aortic arch along 
with the thoracic aorta. 
Unfortunately, despite the higher uptake, the 
[18F]ZCDD083 signal in these small sized atherosclerotic 
plaques was affected by partial volume effect and, due to the 
limited spatial resolution of PET,32 no “hotspots” could be 
detected in the in vivo imaging studies. Indeed, the vessel 
wall in mouse aorta is usually 30-80 µm, whereas the 
resolution in rodent PET imaging is ~1,2 mm. 
The specificity of the tracer accumulation at the target 
structure (i.e. atherosclerotic plaque) was demonstrated by 
the combination of ex vivo autoradiography with en face Oil 
Red O staining of the same aortic specimens. Indeed, we 
observed co-localisation of [18F]ZCDD083 signal with 
plaque distribution along the aorta. These cross studies, 
involving C57BL/6J, ApoE-/- and ApoE−/−Fbn1C1039G+/− 
demonstrated high sensitivity of [18F]ZCDD083 to detect 
atherosclerotic plaques, whereas little signal was detected 
in normal vessel or outside atherosclerotic lesions. These 
stained areas exhibited a higher tracer accumulation. 
Hence, the [18F]ZCDD083 uptake was clearly correlated 
with plaque distribution as well as with the progression of 
the disease. 
CONCLUSION
In summary, we efficiently radio-synthesized the novel 
PET tracer [18F]ZCDD083 which targets the 
PFKFB3enzyme. Using in vivo and ex vivo studies, we 
characterized and validated [18F]ZCDD083, demonstrating 
its ability to detect atherosclerotic plaques. This tracer may 
represent a promising tool for the non-invasive diagnosis 
and follow-up of atherosclerotic plaques prone to rupture, 
which in turn could help improving risk stratification and 
evaluation of the efficacy of anti-atherosclerotic therapies. 
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